A survey of multiple transplant centers found a lack of consistent use of comprehensive screening for chronic GVHD; lead ...

Andrew Evens, DO, and Joanna Rhodes, MD, on CLL's transformation, CAR T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across New Jersey.

Agentic AI in oncology distills evidence, molecular data, and guidelines to aid therapy decisions, promising smarter, context ...

Although he typically prefers to minimize time spent in the hospital and has an hour-long commute to the academic center, he understands that CAR T-cell therapy requires treatment at a specialized ...

Among the evidence cited is the 5-year follow-up of the ICE3 trial, a single-arm, multicenter study of cryoablation without ...

The FDA has granted fast track designation to safusidenib, an oral IDH1 inhibitor, based on durable phase 2 J201 study ...

The FDA has granted breakthrough therapy designation and fast track designation to 68Ga-NYM096, an investigational PET ...

David Savage, MD, PhD, discusses the greater significance of the PFS benefit observed in a trial of darovasertib plus ...

FDA fast track designation was granted for ETX-19477 in BRCA-mutated HR+/HER2– unresectable or metastatic breast cancer, ...

FDA fast track status supports accelerated development of PLN-101095 plus pembrolizumab for ICI-refractory solid tumors, ...

A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and nocturia. He denied significant fatigue and weight loss. He walks 2 to 3 ...

While the survival advantage seen among Asian American women with breast cancer isn't yet ready to shape clinical practice ...